Table 2.

Cancer risks and recommended management options associated with the genes identified in six DH mutation carriers according to the latest NCCN guidelines, Version 3.2024 [63] Can we move columns 4 to 6 more to the right to ensure that Columns 2 and 3 are less cramped?

Gene	Absolute risk of female BC (%)	Other associated cancers	Age of recommended BC screening (MRI/mammogram)	Is risk-reducing mastectomy recommended?*	Is risk-reducing salpingo-oophorectomy recommended?*
BRCA1	> 60	Ovarian, pancreatic, prostate, male BC	25 years	Yes	Yes
BRCA2	> 60	Ovarian, pancreatic, prostate, male BC, melanoma	25 years	Yes	Yes
TP53	> 60	Soft tissue sarcoma, osteosarcoma, CNS tumor, ACC, melanoma, colorectal, prostate, gastric, pancreatic ca	20 years	Yes	n/a
ATM	20–30	Pancreatic, prostate, ovarian ca	30 years	No	No
BARD1	17–30	Unknown or insufficient evidence	40 years	No	n/a
FANCD2	Unknown or insufficient evidence	Unknown or insufficient evidence	n/a	n/a	n/a
NBN	Unknown or insufficient evidence	Unknown or insufficient evidence	n/a	n/a	n/a

BC - breast cancer, CNS - central nervous system, ACC - adrenocortical carcinoma, ca - cancer, n/a - not applicable

*Based on molecular diagnosis alone. Surgery can be considered for all cases with a significant family history of the disease